

Corporate Overview

Asset-Centric. **K**Patient-Centric.

Disclaimer

This presentation has been prepared by Centessa Pharmaceuticals plc (the "Company") for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor's particular objectives, financial situation or needs. The communication of this presentation may be restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements, including, without limitation, statements related to the Company's ability to deliver impactful medicines to patients; the ability of our key executives to drive execution of the Company's portfolio of programs; our asset-centric business model and the intended advantages and benefits thereof; research and clinical development plans; the scope, progress, results and costs of developing our product candidates or any other future product candidates; the development and therapeutic potential of our product candidates, including SerpinPC, LB101, MGX292, OX2R and our LockBody platform; strategy; regulatory matters, including the timing and likelihood of success of obtaining approvals to initiate or continue clinical trials or market any products; market size and opportunity for our product candidates; and our anticipated cash runway. Words such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," "aim," "seek," and variations of these words or similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including, without limitation, risks related to our ability to protect and maintain our intellectual property position; business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing products and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned CENTESSA

clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; future expenditures risks related to our asset-centric corporate model; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and risks related to the COVID-19 pandemic including the effects of the Delta, Omicron and any other variants, geo-political risks such as the Russia-Ukraine conflict and other risk factors contained in our filings with the U.S. Securities and Exchange Commission. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. All projections, valuations and statistical analyses are provided for information purposes only. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory agency. No representation or warranty, express or implied, is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company's own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation or warranty, express or implied, as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Discovering and developing medicines that are transformational for patients



Multiple potential blockbuster assets



Cash runway into 2026 enables clinical readouts across portfolio




World-class R&D team



Note: **\$444.8 million** in cash and cash equivalents as of September 30, 2022.

DIFFERENTIATION

We are a transformational pharmaceutical company fueling an innovative pipeline



MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION

Lead Assets	Disease	Estimated Market Size [*]	
SerpinPC	Hemophilia B	\$2B+1	
LB101	Solid Tumors	\$10B ¹	
MGX292	Pulmonary Arterial Hypertension (PAH)	\$6 B ¹	
OX2R Agonists	Narcolepsy (NT1)	\$2 B+ ¹	

*Source: ¹Evaluate Pharma 2021 and internal estimates Centessa has several earlier stage programs that are not reflected on this slide. 4

NNOVATIVE PIPELINE Potential first-in-class/ best-in-class medicines for patients

	PRE-CLINICAL	PHASE 1	PHASE 2	REGISTRATIONAL
SerpinPC in Hemophilia (Hemophilia B registrational development	nt program)			
LB101 in Solid Tumors				
MGX292 in Pulmonary Arterial Hypertension (PAH)				
OX2R Agonists in Narcolepsy (NT1)				
CBS001 in Inflammatory/ Fibrotic Diseases				
CBS004 in Systemic Sclerosis, Lupus Erythematosus				


CASH RUNWAY INTO 2026 ENABLES CLINICAL READOUTS ACROSS PIPELINE

\$444.8 million in cash and cash equivalents as of September 30, 2022.



Additional LockBody[®] molecules, such as LB201 are being progressed toward candidate selection expected early 2023. Centessa has several earlier stage programs that are not reflected on this slide.


LEADERSHIP Team with deep R&D experience and focused on execution



SerpinPC in Hemophilia




SerpinPC has potentially best-in-class attributes to address unmet need in hemophilia B Novel MOA; designed to prevent and reduce bleeds without risk of thrombosis



SerpinPC is a serine protease inhibitor (SERPIN) engineered to specifically inhibit activated protein C (APC) and is being developed for the treatment of hemophilia. *Source: 1.Evaluate Pharma 2021 2. 6-month repeat-dose portion of Phase 2a Study conducted in Georgia and Moldova to evaluate safety, tolerability, pharmacokinetics and efficacy of SerpinPC in a population of severe hemophilia A and B subjects not on previous prophylaxis and with a history of frequent bleeding.

SerpinPC is believed to have a unique MoA supported by human genetics

Primary APC is the target of SerpinPC




SerpinPC

- Human genetic target validation
- Engineered to specifically inhibit APC
- Inhibition of APC increases thrombin
- Feedback loop prevents excess thrombin generation

Phase 2a Study: SerpinPC showed significant reductions in bleeding rates

Median ABR reduction for highest dose cohort (1.2 mg/kg)



SerpinPC was also observed to be well-tolerated

Across all dose levels:

- 😢 No thrombosis
- No instances of sustained elevations in D-dimer


One moderate skin reaction led to withdrawal of a subject with history of a skin disorder. Two subjects with ADAs, with no apparent impact on ABRs. No other SerpinPC-related AEs.

ABR is annualized bleeding rate.

Six-month update of Phase 2a Study conducted in Georgia and Moldova to evaluate safety and efficacy of SerpinPC in a population of severe Hemophilia A and B subjects not on previous prophylaxis and with a history of substantial bleeding.




Phase 2a Study: Individual observed ABRs for all bleeds and spontaneous joint bleeds






Phase 2a Study: Individual observed ABRs across dose cohorts





SerpinPC registrational development plan (Hemophilia B without inhibitors)

1 ≥12 Week Observation Study (# PRESent-5): Designed to enroll patients and prospectively establish baseline ABR before initiation of interventional studies




*Primary Endpoint: Rate of treated bleeds (expressed as ABR) in the observation period and during the first 24 weeks with SerpinPC



SerpinPC registrational development plan (Hemophilia B with inhibitors)

1 ≥12 Week Observation Study (# PRESent-5): Designed to enroll patients and prospectively establish baseline ABR before initiation of interventional studies




*Primary Endpoint: Rate of treated bleeds (expressed as ABR) in the observation period and during the first 24 weeks with SerpinPC



LB101 O in Solid Tumors




LB101: Potential first-in-class immunotherapy targeting solid tumors A conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody






LB101: Designed to optimally deliver PD-L1 targeted anti-CD47 activity to the TME



Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum 1. Constitutive Fabs drive tumor enrichment

2. Natural cleavage of IgG-derived hinges in tumors UNLOCKED




Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes



LB101 showed improved efficacy and durability over atezolizumab in a difficult-to-treat mouse model while being well tolerated

In vivo: Systemically delivered LB101 exhibited significant tumor regression



weight loss 40.0 lgG1 lsotype, 10mg/kg, 10 µl/g, i.p. 35.0 Atezolizumab, 5mg/kg, 10 μl/g, i.p. Mean Body Weight (g) SEM 30.0 Atezolizumab, 10mg/kg, 10 µl/g, i.p. 25.0 LB101, 8.5mg/kg, 10 µl/g, i.p. 20.0 LB101, 17 mg/kg, 10 µL/g, i.p. 15.0 10.0 5.0 0.0 20 30 40 50 10 Study Days


In vivo: LB101 was well tolerated with no



LB101 shown to be safe and well tolerated in non-human primates up to 50 mg/kg weekly x 4 weeks Pharmacokinetics Bodyweight

In-vivo: LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates

- Human IgG1-like PK •
- No adverse observations •
 - No anemia or thrombocytopenia -
 - No changes in pathology, clinical chemistry or coagulation parameters



Study Day



- 50 ma/ka (f)

20

- 50 ma/ka (f

50 ma/ka (f)

0

10 15


Davs post-dose

MGX292 in Pulmonary Arterial Hypertensior




MGX292: Potential for disease modification in patients with PAH

Protein-engineered variant of BMP9, selective for BMPR2/ALK2



Preclinical Data: MGX292 demonstrated dosedependent normalization of established lung vascular pathology in Sugen-hypoxia rat model

MGX292¹ shown to modify neointimal lesions in Sugen-hypoxia rat model of severe PAH






OX2R Agonists in NT1




OX2R Agonists: Potential to change the standard of care for narcolepsy



Structure-based drug design has enabled the discovery of OX2R agonists with potential as orexin signaling replacement therapy for NT1

Discovery compounds have demonstrated **sub-nanomolar potency** in *in vitro* assays *

* Based on EC50, *in vitro* functional profiles of exemplar small molecule agonists and exemplar peptide agonists in a calcium mobilization FLIPR assay with cells expressing recombinant human OX2R






Example Cryo-EM structure of OX2R with peptide agonist (shown in purple)

Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple)



Novel OX2R agonists increased wakefulness in WT and NT1 mice



Novel small-molecule
OX2R agonists from
multiple lead series
increased wakefulness in
healthy mice and in an
NT1 mouse model.

 The newest compounds showed substantially increased potency in NT1 mice and are progressing rapidly through the discovery pipeline.



Poster Presentation entitled, "Novel Orexin Receptor-2 Agonists Developed Using Structure-based Drug Design: Prototype Compounds Promote Wakefulness and Reduce Cataplexy in Orexin/Ataxin-3 and WT Mice." Presented at 26th Conference of the European Sleep Research Society, Sept. 30, 2022. Note: Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefulness by unsupervised machine learning.

Centessa is fueling multiple pathways to value creation



Multiple potential blockbuster assets



Cash runway into 2026 enables clinical readouts across pipeline



World-class R&D team

Note: \$444.8 million in cash and cash equivalents as of September 30, 2022.



